Novo Nordisk‘s operating profit declined more than analysts anticipated, prompting the pharmaceutical giant to lower its full-year outlook, the company announced today. The Danish drugmaker cited increased investment in its weight-loss drug Wegovy and its diabetes treatment Ozempic as key factors impacting profitability.
The reduced forecast signals potential headwinds for Novo Nordisk as it navigates surging demand for its blockbuster weight-loss medication and prepares for increased competition in the market.Investors and healthcare providers are closely watching the company’s performance, given the notable impact wegovy and Ozempic have on the treatment of obesity and type 2 diabetes, respectively.
According to data released by the company, profit before tax decreased to 25,517 million Danish krone, a 25.8% decline from 34,384 million krone in the prior period. Net result also fell, dropping 26.7% to 20,006 million Danish krone from 27,301 million danish krone.
The consensus data,sourced from Bloomberg and reported by news agency Finwire,underscores the unexpected scale of the profit reduction. Reno Santic of finwire reported the news via Twitter (@finwire) and indicated further details are available at newsroom@finwire.se.
